Quote this publication Share Print

MABTHERA

-
Opinions on drugs - Posted on Mar 19 2013

Reason for request

Inclusion for hospital use in the extension of indication for maintenance treatment of follicular lymphoma in previously untreated patients.

-


Clinical Benefit

Substantial

The actual benefit of MabThera in the maintenance treatment of previously untreated non-Hodgkin's follicular lymphoma is substantial.


Clinical Added Value

important

MabThera as maintenance treatment for previously untreated follicular lymphoma, provides an important improvement in actual benefit (IAB II) in terms of efficacy in the management of patients who respond to first-line induction therapy.


Contact Us

Évaluation des médicaments

See also